Navidea Biopharmaceuticals, Inc. announced that it has entered into a Stock Purchase Agreement with two accredited investors pursuant to which the company agreed to issue a private placement a total of 11,000 shares of Series J convertible preferred stock at a price of $100 per share for the gross proceeds of $1,100,000 on May 22, 2023.The Company also agreed to provide the investors with certain registration rights related to the resale of the shares of the company's common stock, par value $0.001 per share issuable upon conversion of the Series J preferred stock.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | 0.00% | 0.00% | -99.82% |
1st Jan change | Capi. | |
---|---|---|
-99.82% | 10K | |
+48.67% | 54.63B | |
-6.38% | 39.92B | |
+37.07% | 38.82B | |
+14.35% | 26.86B | |
-11.17% | 26.22B | |
-21.95% | 18.78B | |
+26.58% | 12.21B | |
+0.93% | 12.16B | |
+27.80% | 11.94B |
- Stock Market
- Equities
- NAVB Stock
- News Navidea Biopharmaceuticals, Inc.
- Navidea Biopharmaceuticals, Inc. announced that it expects to receive $1.1 million in funding